Monday, 19 November 2012

Poll result: Is Genzyme morally corrupt?

This poll was done in relation to Genzyme's decision to withdraw Campath (alemtuzumab) from the market and thereby prevent further off-label use of the drug in MSers until the new version is licensed for treating RRMS! 

Jeremy Laurance. Neurologists appeal to health secretary over withdrawal of drug for MS patients. BMJ 2012; 345 doi: http://dx.doi.org/10.1136/bmj.e7449 (Published 2 November 2012)

..... The doctors said they are disappointed by the actions of Genzyme, a subsidiary of the multinational drug company Sanofi. One called the company “morally corrupt” for disrupting the treatment of patients in favour of future profits.....




"The result of this poll speaks for itself! A hung result. It appears that no side has won the argument and the perspective of the British neurologist, who made this claim, is not shared by all. The message for Genzyme is that they need to explain their position to the readers of this blog and make the case, why they had to withdraw Campath from the market, clear! I personally don't think silence is an option!" 


10 Nov 2012
Poll of the week: "Is Genzyme morally corrupt?" Jeremy Laurance. Neurologists appeal to health secretary over withdrawal of drug for MS patients. BMJ 2012; 345 doi: http://dx.doi.org/10.1136/bmj.e7449 (Published 2 ...

20 Aug 2012
This means that alemtuzumab will no longer be available as a licensed product in the UK once existing supplies run out. This action is not being taken for any reasons related to product safety, efficacy or supply, but as part of ...
22 Aug 2012
Alemtuzumab remains in the news. Sanofi pulls Campath to clear way for higher-priced Lemtrada FiercePharma. Genzyme has been developing Campath-slash-Lemtrada for MS, hoping to become a big player in that disease ...
27 Aug 2012
Cambridge, MA – August 27, 2012 – Genzyme has announced that it has received a "Refuse to File" letter from the U.S. Food and Drug Administration (FDA) in response to the supplemental Biologics License Application ...
21 Aug 2012
Alemtuzumab is being pulled in the US as well. (Reuters) - Sanofi's rare disease unit Genzyme is pulling leukaemia drug Campath to prepare for its launch under a different dosage and as a multiple sclerosis treatment that ...

01 Nov 2012
Maybe more risks with alemtuzumab will emerge later, but the mayor risks with tysabri are well-documented- PML if you're JCVe+, and if you decide to come off it IRIS, and now these recent cases of fulminant MS in MSers ...
01 Nov 2012
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. The Lancet, Early Online Publication, 1 November 2012 doi:10.1016/S0140-6736(12)61768-1.
28 Oct 2012
"The aim of this presentation was to present the phase 3 trial data on Alemtuzumab in early RRMS as a therapeutic strategy that probably works by depleting circulating lymphocytes. The slides may be a little complicated as ...

28 Aug 2012
The graph below compares the search volume index of alemtuzumab to CCSVI. To make the graphs readable I had to do a log conversion of the search volumes, which are given by week. To do the log conversion I simply ...
05 Sep 2012
"Yesterday's post on the withdrawal of alemtuzumab to prevent off-license use of the oncology version of alemtuzumab (Mabcampath) resulted in a flurry of discussion and criticism. With some of the latter occurring off-line.
21 Aug 2012
"Yesterday's post on the withdrawal of alemtuzumab to prevent off-license use of the oncology version of alemtuzumab (Mabcampath) resulted in a flurry of discussion and criticism. With some of the latter occurring off-line.
28 Aug 2012
Genzyme must resubmit Lemtrada application to FDA Boston Herald Sanofi subsidiary, Genzyme Corp. of Cambridge, said today it has received a refuse to file letter from the U.S. Food and Drug Administration for approval of ...

CoI: Multiple

5 comments:

  1. I wonder how many of the no votes came from Genzyme or pharma people.

    ReplyDelete
    Replies
    1. My thoughts exactly too! I said 'maybe' although I tend towards 'corrupt' but am not 100% sure.

      Delete
    2. Unlikely to be us pharma; google tracks IP addresses and we are banned from voting on social networking sites. Imagine the scandal if Pharma was exposed manipulating polls?

      Delete
  2. Google does track IP addresses but who gets to see them?

    "If Pharma was exposed manipulating polls"....this is the least of pharmas problems in what they manipulate

    ReplyDelete

Please note that all comments are moderated and any personal or marketing-related submissions will not be shown.